STML Stemline Therapeutics, Inc.

8.50
0  -5%
Previous Close 8.95
Open 9.00
Price To book 2.78
Market Cap 152.58M
Shares 17,951,000
Volume 367,517
Short Ratio 1.67
Av. Daily Volume 437,385

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing. ASH oral presentation - December 2016.
SL-401
High Risk Myeloproliferative Neoplasms
Phase 2 enrollment to be completed 1Q 2017. Data due 2H 2017.
SL-401
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer
Phase 2 preliminary data released November 2016.
SL-701
Second line glioblastoma (GBM) cancer
Phase 2 ongoing. ASH oral presentation - December 2016.
SL-401
Cancer- adult relapsed or refractory acute myeloid leukemia (AML)

Latest News

  1. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Stemline Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – STML
  2. INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  3. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017
  4. Blog Coverage Stemline Announces Completion of Enrollment for the Stage 3 SL-401 Pivotal Trial
  5. STEMLINE THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  6. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors In Stemline Therapeutics, Inc. Of Imminent Lead Plaintiff Deadline
  7. STEMLINE THERAPEUTICS INC Financials
  8. Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN
  9. INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm
  10. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc.
  11. SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  12. Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  13. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017
  14. IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm
  15. Stemline Investors Reminder: Hagens Berman Reminds Investors in Stemline Therapeutics of the April 4, 2017 Lead Plaintiff Deadline
  16. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Stemline Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline
  17. SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm
  18. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc.
  19. Shareholder Deadline Reminder (STML): Johnson & Weaver, LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics and Encourages Investors with Losses to Contact the Firm
  20. STEMLINE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and